On May 27, 2022 Daewoong Pharmaceutical reported on the 23rd that it signed a business agreement (MOU) with Nexi, a bio venture specializing in new drug development, for joint research and development of immunotherapy anti-cancer drugs and mid- to long-term cooperation (Press release, NEX-I, MAY 27, 2022, View Source;mode=VIEW&num=16&category=&findType=&findWord=&sort1=&sort2=&page=3 [SID1234643433]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
According to the announcement, NexI is developing new antibody drugs by targeting new immunotherapy refractory factors based on its proprietary platform technology. We plan to develop treatments alone or in combination with existing immunotherapy agents for cancer patients who cannot use immunotherapy agents or who do not respond to existing anticancer agents.
Through this agreement, Daewoong Pharmaceutical and NexI plan to jointly research and develop NexI’s pipeline, including the non-small cell lung cancer (NSCLC) antibody candidate ‘NXI-101’ and the metastatic melanoma antibody candidate ‘NXI-201’.
In particular, Daewoong Pharmaceutical plans to participate as a strategic investor (SI) in NexI’s Pre-A series investment, cooperate with NexI in overseas licensing out, and build various business models through mid- to long-term cooperation.
Seung-ho Jeon, CEO of Daewoong Pharmaceutical, said, "It is encouraging to be able to cooperate in the field of research and development with NexI, whose excellent technology has been proven through selection as a national project." He added, "We will continue to research innovative new drugs in the field of immunotherapy through open collaboration, which is Daewoong Pharmaceutical’s research and development strategy. "I will focus on this," he said.
Kyung-wan Yoon, CEO of Nexi, said, "We are pleased to have entered into a cooperative relationship with Daewoong Pharmaceutical," and added, "We will strive to achieve innovative results in the field of new immunotherapy drug development through close cooperation between the two companies in the future."